CRNBs according to study over time PS-matched, Kaplan-Meier estimated cumulative proportion of patients in PR, raw numbers of bleeds, and weighted negative-binomial distributed mean CRNB rates per patient-week are given
| Time (wk) . | Immunosuppression (GTH-AH 01/2010), N = 101 . | Emicizumab (GTH-AHA-EMI), N = 47 . | ||||
|---|---|---|---|---|---|---|
| PR (%) . | Bleeds (n) . | Bleeding rate . | PR (%) . | Bleeds (n) . | Bleeding rate . | |
| 1-12∗ | 78 | 127 | 0.128 | 1 | 22 | 0.042 |
| 13-24 | 82 | 9 | 0.010 | 24 | 18 | 0.034 |
| 25-36 | 84 | 1 | 0.002 | 41 | 5 | 0.009 |
| 37-48 | 84 | 1 | 0.002 | 62 | – | – |
| 49-60 | 85 | 1 | 0.003 | 62 | 1 | 0.002 |
| 61-72 | 85 | – | – | 69 | 1 | 0.002 |
| 73-84 | 85 | – | – | 73 | – | – |
| 85-96 | 85 | – | – | 81 | – | – |
| Time (wk) . | Immunosuppression (GTH-AH 01/2010), N = 101 . | Emicizumab (GTH-AHA-EMI), N = 47 . | ||||
|---|---|---|---|---|---|---|
| PR (%) . | Bleeds (n) . | Bleeding rate . | PR (%) . | Bleeds (n) . | Bleeding rate . | |
| 1-12∗ | 78 | 127 | 0.128 | 1 | 22 | 0.042 |
| 13-24 | 82 | 9 | 0.010 | 24 | 18 | 0.034 |
| 25-36 | 84 | 1 | 0.002 | 41 | 5 | 0.009 |
| 37-48 | 84 | 1 | 0.002 | 62 | – | – |
| 49-60 | 85 | 1 | 0.003 | 62 | 1 | 0.002 |
| 61-72 | 85 | – | – | 69 | 1 | 0.002 |
| 73-84 | 85 | – | – | 73 | – | – |
| 85-96 | 85 | – | – | 81 | – | – |
Results of the first 12-week period were already published.22